XCUR EXICURE, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1698530 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-97.7%
TTM net income YoY-235.0%
TTM EPS YoY65.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,228.2%
Net margin-801.4%
FCF margin—
EBITDA margin-1,222.6%
Returns
ROE-132.6%
ROA-34.0%
ROIC (approx.)-326.7%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets85.5%
Debt / equity0.00x
Current ratio0.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $500,000 | $0 | $28.83M | -$483,000 |
| R&D expense | $3.29M | $0 | $1.42M | $19.77M | $48.98M |
| SG&A expense | $6.83M | $5.45M | $11.71M | $10.89M | $13.09M |
| Operating income | -$4.23M | -$12.23M | -$15.00M | -$1.83M | -$62.55M |
| Interest expense | $1,000 | $18,000 | $0 | $595,000 | $1.69M |
| Pretax income | -$5.58M | -$9.69M | -$16.91M | -$2.37M | -$64.10M |
| Income tax | -$634,000 | $8,000 | $0 | $209,000 | $0 |
| Net income | -$4.95M | -$9.70M | -$16.91M | -$2.58M | -$64.10M |
| EBITDA | -$3.99M | -$12.20M | -$14.36M | -$668,000 | -$61.43M |
| EPS (basic) | -0.79 | -4.75 | -10.55 | -0.56 | -21.70 |
| EPS (diluted) | -0.79 | -4.75 | -10.55 | -0.56 | -21.70 |
| Weighted avg. shares (diluted) | 6.30M | 2.04M | 1.60M | 4.62M | 2.95M |
| Balance sheet | |||||
| Cash & equivalents | $3.75M | $12.51M | $2.02M | $9.78M | $43.84M |
| Short-term investments | — | — | — | $0 | $4.50M |
| Receivables | — | — | — | — | $0 |
| Current assets | $4.62M | $13.67M | $2.02M | $10.05M | $43.67M |
| PP&E, net | $306,000 | $26,000 | $54,000 | $2.53M | $3.93M |
| Goodwill | $4.40M | $0 | — | — | — |
| Intangibles | $3.78M | $0 | — | — | — |
| Total assets | $14.04M | $15.06M | $11.58M | $23.33M | $64.87M |
| Current liabilities | $3.89M | $3.07M | $2.51M | $1.64M | $34.07M |
| Short-term debt | — | — | $0 | $0 | $6.87M |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $6.87M |
| Total liabilities | $10.12M | $8.28M | $8.55M | $8.41M | $53.64M |
| Shareholders' equity | $3.93M | $6.77M | $3.03M | $14.92M | $11.23M |
| Net debt | — | — | — | — | -$36.97M |
| Shares outstanding | 6.37M | 6.03M | 1.83M | 4.97M | 3.63M |
| Cash flow statement | |||||
| Operating cash flow | -$8.55M | -$2.91M | -$10.36M | -$35.66M | -$34.82M |
| Capital expenditure | $1,000 | $0 | $0 | $10,000 | $968,000 |
| Free cash flow | -$8.56M | -$2.91M | -$10.36M | -$35.67M | -$35.79M |
| Investing cash flow | -$1.81M | $0 | -$1.08M | $4.70M | $43.09M |
| Financing cash flow | $1.60M | $13.40M | $3.67M | -$3.10M | $1.12M |
| Depreciation & amortization | $242,000 | $28,000 | $634,000 | $1.16M | $1.12M |
| Stock-based compensation | $2,000 | $22,000 | $1.35M | $1.37M | $2.94M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.